Alexander M.M. Eggermont
Inserm · 1,343 works · 100,762 citations · h-index 139
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- Improved Endpoints for Cancer Immunotherapy Trials
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
- Delivering affordable cancer care in high-income countries
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- Global cancer surgery: delivering safe, affordable, and timely cancer surgery
- A Clinical Development Paradigm for Cancer Vaccines and Related Biologics